Case report: The remarkable response of pembrolizumab combined with RC48 in the third-line treatment of metastatic urothelial carcinoma

BACKGROUND: Systemic chemotherapy has been the mainstay treatment for locally advanced or metastatic urothelial carcinoma (UC). In the past few years, novel immune checkpoint inhibitors (ICIs) and antibody-drug conjugates (ADCs) have improved the treatment of advanced UC. CASE PRESENTATION: Here, we...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Zhenying, Ma, Jiaman, Chen, Ting, Yang, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9705978/
https://www.ncbi.nlm.nih.gov/pubmed/36458005
http://dx.doi.org/10.3389/fimmu.2022.978266

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9705978/
https://www.ncbi.nlm.nih.gov/pubmed/36458005
http://dx.doi.org/10.3389/fimmu.2022.978266

Ejemplares similares